Investors & Media

Transformative science, targeted medicines

Blueprint Medicines is a fully integrated global biopharmaceutical company that invents life-changing medicines across two strategic focus areas of allergy/inflammation and oncology/hematology. Our approach combines deep scientific expertise, modality-agnostic drug discovery capabilities, and a proven track record of R&D success. Currently, we are commercializing our approved medicine AYVAKIT/AYVAKYT® (avapritinib) in the U.S. and Europe, as well as in other regions of the world through partnerships.

SEC Filings

SEC Filings

Search
Filing date Form Description View
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-19-009779.pdf
0001179110-19-009779.rtf
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-19-009747.pdf
0001179110-19-009747.rtf
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-19-009748.pdf
0001179110-19-009748.rtf
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-19-009746.pdf
0001179110-19-009746.rtf
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-19-009617.pdf
0001179110-19-009617.rtf
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-19-009616.pdf
0001179110-19-009616.rtf
8-K

Report of unscheduled material events or corporate event

 View HTML
0001558370-19-006735.pdf
0001558370-19-006735.rtf
0001558370-19-006735.xls
10-Q

Quarterly report which provides a continuing view of a company's financial position

 View HTML
0001558370-19-006820.pdf
0001558370-19-006820.rtf
0001558370-19-006820.xls
EX-101.SCH - EX-101.SCH
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-19-008768.pdf
0001179110-19-008768.rtf
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-19-008727.pdf
0001179110-19-008727.rtf